NEW YORK--(BUSINESS WIRE)--
Bragar Eagel & Squire, P.C. is investigating potential claims against United Therapeutics Corporation (NASDAQ:UTHR). Our investigation concerns whether United Therapeutics has violated the federal securities laws and/or engaged in other unlawful business practices.
On July 27, 2017, UTHR disclosed that they “are engaged in settlement negotiations with the DOJ” and that they “expect any such settlement would include a settlement payment to the government, and it may also include non-monetary obligations, such as entering into a corporate integrity agreement (CIA).” They further stated that “We may be required to incur significant future costs to comply with the CIA” and that “during the second quarter of 2017, we recorded a $210.0 million accrual relating to this matter.”
Following this news, shares of United Therapeutics fell $6.30, or 4.79%, to close at $125.10 on July 27, 2017.
If you purchased or otherwise acquired United Therapeutics securities and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into United Therapeutics Corporation, please go to http://www.bespc.com/UTHR. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170727006627/en/
